Ross S Liao1, Mohit Gupta2, Zeyad R Schwen2, Hiten D Patel2, Max Kates3, Michael H Johnson3, Noah M Hahn4, David McConkey3, Trinity J Bivalacqua5, Phillip M Pierorazio4. 1. Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: rliao4@jhmi.edu. 2. Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland; The Greenberg Bladder Cancer Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland; The Greenberg Bladder Cancer Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract
PURPOSE: High risk upper tract urothelial carcinoma has been associated with poor survival outcomes. Limited retrospective data support neoadjuvant chemotherapy prior to radical nephroureterectomy. To validate prior findings we evaluated differences in the pathological stage distribution in patients with high risk upper tract urothelial carcinoma based on the administration of neoadjuvant chemotherapy before radical nephroureterectomy. MATERIALS AND METHODS: We retrospectively analyzed the records of 240 patients with upper tract urothelial carcinoma at The Johns Hopkins Hospital from 2003 to 2017. Patients with biopsy proven high grade disease and a visible lesion on cross-sectional imaging were offered neoadjuvant chemotherapy prior to radical nephroureterectomy. A control group of a time matched cohort of patients with biopsy proven high grade disease underwent extirpative surgery alone. The chi-square and Fisher exact tests were used to evaluate clinical and pathological variables between the cohorts. RESULTS: There were 32 patients in the study group and 208 in the control group. Significantly lower pathological stage was noted in the study group than in the control group (p <0.001). Significantly fewer patients with pT2 disease or higher were treated with neoadjuvant chemotherapy (37.5% vs 59.6%, p = 0.02). There was a 46.5% reduction in the prevalence of pT3 disease or higher in study group patients without clinically node positive or low volume metastatic disease (25.9% vs 48.4%, p = 0.04). A 9.4% complete remission rate was observed in patients who underwent neoadjuvant chemotherapy. CONCLUSIONS: Patients with high risk upper tract urothelial carcinoma treated with neoadjuvant chemotherapy were noted to have a lower pathological stage distribution than patients treated with radical nephroureterectomy alone.
PURPOSE: High risk upper tract urothelial carcinoma has been associated with poor survival outcomes. Limited retrospective data support neoadjuvant chemotherapy prior to radical nephroureterectomy. To validate prior findings we evaluated differences in the pathological stage distribution in patients with high risk upper tract urothelial carcinoma based on the administration of neoadjuvant chemotherapy before radical nephroureterectomy. MATERIALS AND METHODS: We retrospectively analyzed the records of 240 patients with upper tract urothelial carcinoma at The Johns Hopkins Hospital from 2003 to 2017. Patients with biopsy proven high grade disease and a visible lesion on cross-sectional imaging were offered neoadjuvant chemotherapy prior to radical nephroureterectomy. A control group of a time matched cohort of patients with biopsy proven high grade disease underwent extirpative surgery alone. The chi-square and Fisher exact tests were used to evaluate clinical and pathological variables between the cohorts. RESULTS: There were 32 patients in the study group and 208 in the control group. Significantly lower pathological stage was noted in the study group than in the control group (p <0.001). Significantly fewer patients with pT2 disease or higher were treated with neoadjuvant chemotherapy (37.5% vs 59.6%, p = 0.02). There was a 46.5% reduction in the prevalence of pT3 disease or higher in study group patients without clinically node positive or low volume metastatic disease (25.9% vs 48.4%, p = 0.04). A 9.4% complete remission rate was observed in patients who underwent neoadjuvant chemotherapy. CONCLUSIONS:Patients with high risk upper tract urothelial carcinoma treated with neoadjuvant chemotherapy were noted to have a lower pathological stage distribution than patients treated with radical nephroureterectomy alone.
Authors: Hiten D Patel; Maneka Puligandla; Brian M Shuch; Bradley C Leibovich; Anil Kapoor; Viraj A Master; Charles G Drake; Daniel Yc Heng; Primo N Lara; Toni K Choueiri; Deborah Maskens; Eric A Singer; Scott E Eggener; Robert S Svatek; Walter M Stadler; Suzanne Cole; Sabina Signoretti; Rajan T Gupta; Marc Dror Michaelson; David F McDermott; David Cella; Lynne I Wagner; Naomi B Haas; Michael A Carducci; Lauren C Harshman; Mohamad E Allaf Journal: Future Oncol Date: 2019-04-10 Impact factor: 3.404
Authors: Kwanghee Kim; Wenhuo Hu; François Audenet; Nima Almassi; Aphrothiti J Hanrahan; Katie Murray; Aditya Bagrodia; Nathan Wong; Timothy N Clinton; Shawn Dason; Vishnu Mohan; Sylvia Jebiwott; Karan Nagar; Jianjiong Gao; Alex Penson; Chris Hughes; Benjamin Gordon; Ziyu Chen; Yiyu Dong; Philip A Watson; Ricardo Alvim; Arijh Elzein; Sizhi P Gao; Emiliano Cocco; Alessandro D Santin; Irina Ostrovnaya; James J Hsieh; Irit Sagi; Eugene J Pietzak; A Ari Hakimi; Jonathan E Rosenberg; Gopa Iyer; Herbert A Vargas; Maurizio Scaltriti; Hikmat Al-Ahmadie; David B Solit; Jonathan A Coleman Journal: Nat Commun Date: 2020-04-24 Impact factor: 14.919
Authors: David D'Andrea; Surena Matin; Peter C Black; Firas G Petros; Homayoun Zargar; Colin P Dinney; Michael S Cookson; Wassim Kassouf; Marc A Dall'Era; John S McGrath; Jonathan L Wright; Andrew C Thorpe; Todd M Morgan; Jeffrey M Holzbeierlein; Trinity J Bivalacqua; Srikala S Sridhar; Scott North; Daniel A Barocas; Yair Lotan; Andrew J Stephenson; Bas W van Rhijn; Philippe E Spiess; Siamak Daneshmand; Shahrokh F Shariat Journal: BJU Int Date: 2020-10-14 Impact factor: 5.588